Further studies by Richard (79) and Bufi (80) on different molecular subtypes of breast cancer suggest that ADC value could be used as a predictor of efficacy before NAC in triple-negative type and over-expressed HER2 type breast cancer. This evidence concerns the gene ERBB2 and breast cancer.